Switzerland Pharmaceuticals and Healthcare Report Q2 2013:Life Sciences Market Research Reports

Life Sciences Market Research Reports

Switzerland Pharmaceuticals and Healthcare Report Q2 2013 May 8th 2013, 00:00 BMI View: While the patent cliff and the consequent availability of generic drugs, as well as price cuts on generic medicines and their increasing affordability, will work towards increasing the consumption of generic medicines in Switzerland, BMI believes the government needs to do more to alter patients’ attitudes towards these drugs as this is the main growth deterrent. Headline Expenditure Projections ? Pharmaceuticals: CHF6.58bn (US$7.02bn) in 2012 to CHF6.44bn (US$6.27bn) in 2013; -2.1% decline in local currency terms. ? Healthcare: CHF67.60bn (US$72.11bn) in 2012 to CHF69.71bn (US$67.89bn) in 2013; +3.1% growth in local currency terms. Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=94945. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/switzerland-pharmaceuticals-and-healthcare-report-q2-2013-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions